An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
Dr Robert Mutumba, the head of the Aids Control Programme at the Ministry of Health, told Daily Monitor that Ugandans are ...
Sofosbuvir, a hepatitis C treatment drug, can adversely interact with tenofovir disoproxil, a HIV treatment drug, according to research led by Bingfang Yan, PhD, professor of biomedical and ...
WHO’s 2025 HIV clinical guidelines simplify and strengthen care by recommending more durable, safer treatment regimens, ...
A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths — agonizing, from diseases or infections the body might otherwise fight off — sent loved ones into the streets ...
DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by ...
The US government paused all foreign assistance in January 2025. This abrupt decision affected the delivery of life-saving ...
A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths — agonizing, from diseases or infections the body might otherwise fight off — sent loved ones into the streets ...
Pharma stocks are back in focus as obesity drugs, HIV prevention and biotech deal activity shape the outlook heading into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback